References:
1. Kroger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, et al. Impact of
allogeneic stem cell transplantation on survival of patients less than 65 years of age with
primary myelofibrosis. Blood. 2015;125(21):3347-50.
2. Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, et al. Survival following allogeneic
transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-73.
3. Kroger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and
management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus
process by an EBMT/ELN international working group. Leukemia. 2015;29(11):2126-33.
4. Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, et al.
Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing
stem cell transplantation. Blood. 2019;133(20):2233-42.
5. McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, et al. Myeloablative and
Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in
Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the
European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant.
2019;25(11):2167-71.
6. Klyuchnikov E, Holler E, Bornhauser M, Kobbe G, Nagler A, Shimoni A, et al. Donor lymphocyte
infusions and second transplantation as salvage treatment for relapsed myelofibrosis after
reduced-intensity allografting. Br J Haematol. 2012;159(2):172-81.
7. Oyekunle, A.; Zander, A. R.; Binder, M.; Ayuk, F.; Zabelina, T.; Christopeit, M. et al. (2013):
Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine
kinase inhibitor therapy. In: Ann. Hematol. 92 (4), S. 487–496.
8. Radujkovic, Aleksandar; Dietrich, Sascha; Blok, Henric-Jan; Nagler, Arnon; Ayuk, Francis; Finke,
Jürgen et al. (2019): Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid
Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic
Malignancies Working Party. In: Biol. Blood Marrow Transplant. 25 (10), S. 2008–2016.
9. Jain, Preetesh; Kantarjian, Hagop M.; Ghorab, Ahmad; Sasaki, Koji; Jabbour, Elias J.; Nogueras
Gonzalez, Graciela et al. (2017): Prognostic factors and survival outcomes in patients with
chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of
477 patients. In: Cancer 123 (22), S. 4391–4402.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES